RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note released on Monday,Benzinga reports. They currently have a $10.00 target price on the stock.

Several other analysts have also issued reports on RAPT. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Finally, Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.29.

RAPT Therapeutics Trading Down 5.3 %

Shares of RAPT stock opened at $1.07 on Monday. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $9.65. The business’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.54. The company has a market capitalization of $37.41 million, a P/E ratio of -0.39 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, research analysts predict that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Picton Mahoney Asset Management raised its stake in RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after purchasing an additional 14,697 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the last quarter. Readystate Asset Management LP acquired a new position in RAPT Therapeutics in the third quarter valued at approximately $36,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in RAPT Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Sei Investments Co. purchased a new position in RAPT Therapeutics in the fourth quarter worth approximately $64,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.